Esomeprazole upregulates Nrf2/HO-1 pathway and attenuates profibrotic response in dermal fibroblasts derived from patients with systemic sclerosis.
Koniyan Shaheer S, Khan Mohammad A MA, Ahir Manisha M, Jegga Anil G AG et al.
To investigate whether esomeprazole attenuates profibrotic responses in dermal fibroblasts from patients with systemic sclerosis (SSc), as well as inflammatory and oxidative stress-related responses in dermal endothelial cells, and to evaluate its effects on nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway. To evaluate this, primary dermal fibroblasts from patients with limited SSc were stimulated with transforming growth factor-beta 1 (TGF-β1) to induce profibrotic processes and then treated with esomeprazole. Functional studies showed that esomeprazole reversed aberrant fibroblast contractility, and RNA sequencing (RNA-seq) analysis demonstrated that esomeprazole upregulated antioxidant gene networks and downregulated profibrotic pathways. Intriguingly, the upregulation of HO-1 by esomeprazole was blunted upon genetic deletion of the Nrf2 gene. Microvascular injury is an early event in scleroderma and a precursor of fibrosis. As such, we treated microvascular endothelial cells with the prooxidant molecule bleomycin, with and without esomeprazole, and found that esomeprazole attenuated the expression of pro-inflammatory cytokines. Together, these results suggest that esomeprazole upregulates the Nrf2/HO-1 pathway and attenuates profibrotic responses in SSc dermal fibroblasts and reduces inflammatory and oxidative stress-related responses in dermal endothelial cells, supporting further evaluation of the drug in preclinical scleroderma models.